Provided By GlobeNewswire
Last update: Nov 10, 2025
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, GenesisX™.
Read more at globenewswire.comNYSEARCA:STXS (11/13/2025, 12:44:00 PM)
2.325
-0.1 (-4.32%)
Find more stocks in the Stock Screener


